Logo

IRD

Opus Genetics, Inc.

IRD

Opus Genetics, Inc. • NASDAQ
$2.13 ▲ 5.45% (+0.11)
Market Cap $146.84 M
52w High $2.37
52w Low $0.65
Dividend Yield 0%
P/E -1.15
Volume 195.79K
Outstanding Shares 68.94M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $3.079M ▲ $11.377M ▲ $-17.454M ▼ -566.872% ▼ $-0.25 ▼ $-17.373M ▼
Q2-2025 $2.882M ▼ $5.766M ▼ $-7.42M ▲ -257.46% ▼ $-0.12 ▲ $-8.892M ▼
Q1-2025 $4.37M ▲ $14.299M ▼ $-8.194M ▲ -187.506% ▲ $-0.24 ▲ $-6.809M ▲
Q4-2024 $4.302M ▲ $34.553M ▲ $-35.135M ▼ -816.713% ▼ $-1.11 ▼ $-10.027M ▼
Q3-2024 $3.867M $11.876M $-7.526M -194.621% $-0.29 $-7.526M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $30.815M ▼ $36.122M ▼ $30.155M ▲ $5.967M ▼
Q2-2025 $32.429M ▼ $38.665M ▼ $21.192M ▼ $17.473M ▲
Q1-2025 $41.793M ▲ $48.167M ▲ $43.094M ▲ $5.073M ▼
Q4-2024 $30.323M ▼ $36.862M ▼ $30.138M ▲ $6.724M ▼
Q3-2024 $36.635M $40.389M $6.089M $34.3M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-17.454M ▼ $-6.157M ▲ $0 $4.543M ▲ $-1.614M ▲ $-6.157M ▲
Q2-2025 $-7.42M ▲ $-10.269M ▼ $0 $906K ▼ $-9.363M ▼ $-10.269M ▼
Q1-2025 $-8.194M ▲ $-8.994M ▼ $0 ▼ $20.465M ▲ $11.471M ▲ $-8.994M ▼
Q4-2024 $-35.135M ▼ $-7.438M ▼ $1.21M ▲ $-83K ▼ $-6.311M ▼ $-7.438M ▼
Q3-2024 $-7.526M $-5.13M $0 $353K $-4.777M $-5.13M

Five-Year Company Overview

Income Statement

Income Statement Opus Genetics still looks like a classic early-stage biotech from an income perspective: almost no commercial revenue and results largely driven by research spending and one‑off items. The company briefly showed a small profit a few years ago, but has since returned to losses as development activity has ramped back up. Earnings per share are very volatile, influenced by past share splits and a very small base of revenue. Overall, the income statement tells a story of a company investing ahead of any meaningful product sales, with future results highly dependent on clinical and regulatory milestones rather than current operations.

Balance Sheet

Balance Sheet The balance sheet is lean and dominated by cash, as is typical for a small biotech, with only a modest amount of other assets and essentially no heavy equipment or physical infrastructure. Equity has moved from negative to clearly positive over the past few years, which suggests successful capital raises and a clean-up of past deficits. Debt has been minimal historically, with only a small amount appearing recently, so leverage is still low but has ticked up. The key risk is simply the small absolute size of the balance sheet: the company does not have deep reserves and remains sensitive to future funding conditions and trial outcomes.

Cash Flow

Cash Flow Cash flows underline the development-stage profile. Operating cash flow has hovered around breakeven to mildly negative, reflecting ongoing research and corporate costs with no recurring revenue to offset them. Free cash flow tracks this closely, as capital spending is negligible; the business is not asset‑heavy. The most recent year shows a clear cash burn, meaning the company is consuming cash rather than generating it. Sustainability of this pattern depends on continued access to external capital, milestone payments, or partnerships, as internal cash generation is not yet a realistic source of funding.

Competitive Edge

Competitive Edge Opus is targeting a focused niche within gene therapy: inherited retinal diseases. This area has high unmet medical need and relatively few direct competitors, which gives the company a chance to become a leading specialist rather than fighting in crowded mainstream indications. Its scientific partnerships, including links to top academic centers and patient groups, add credibility and help with trial recruitment and disease understanding. Manufacturing and development collaborations should reduce some execution risk. The flip side is that rare-disease markets are inherently smaller, and success hinges on proving meaningful and durable vision benefits in carefully run trials, under close regulatory scrutiny.

Innovation and R&D

Innovation and R&D Innovation is the core of the story. Opus is developing adeno‑associated virus gene therapies delivered directly under the retina, aiming to correct the underlying genetic faults that cause specific blinding diseases. It is not inventing the entire field from scratch, but is applying proven gene therapy concepts to very precisely defined mutations with a repeatable development “engine” that can be used across multiple programs. Lead candidates are already in early‑stage human trials, with additional programs moving through preclinical work toward regulatory filings. This creates a broad but early pipeline: lots of scientific promise and news flow potential, but also the usual clinical risk that comes with first‑in‑class or first‑in‑indication therapies.

Summary

Opus Genetics is best understood as a high‑risk, research‑driven biotech with a narrow therapeutic focus and a small financial base. The company’s strengths lie in its targeted strategy in inherited retinal diseases, strong scientific pedigree, and a growing pipeline backed by partnerships and regulatory progress. Financially, it remains pre‑revenue, runs operating losses, and depends on external funding to advance its programs, with only modest cash resources and little debt so far. Outcomes for stakeholders will be driven far more by clinical trial data, regulatory decisions, and partnering or financing activity than by current financial performance, making this a story of scientific execution and capital access rather than traditional operating metrics.

NEWS

November 20, 2025 · 8:00 AM UTC

Opus Genetics to Participate in Upcoming Investment Conferences

Read more

November 13, 2025 · 7:00 AM UTC

Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease

Read more

November 12, 2025 · 7:00 AM UTC

Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update

Read more

November 6, 2025 · 7:00 AM UTC

Opus Genetics Announces $23 Million Registered Direct Offering

Read more

November 4, 2025 · 4:01 PM UTC

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more